These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 3486038

  • 1. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 2. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 3. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE, Lipford EH, Mulé JJ, Rosenberg SA.
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [Abstract] [Full Text] [Related]

  • 4. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E, Lafreniere R, Mulé JJ, Schwarz SL, Rosenberg SA.
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [Abstract] [Full Text] [Related]

  • 5. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
    Lafreniere R, Rosenberg SA.
    Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
    [Abstract] [Full Text] [Related]

  • 6. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R, Rosenberg SA.
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [Abstract] [Full Text] [Related]

  • 8. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
    Kedar E, Ben-Aziz R, Shiloni E.
    Isr J Med Sci; 1988 Dec; 24(9-10):494-504. PubMed ID: 3264551
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2.
    Lafreniere R, Borkenhagen K, Bryant LD, Huchcroft S.
    Cancer Res; 1989 May 01; 49(9):2409-14. PubMed ID: 2565160
    [Abstract] [Full Text] [Related]

  • 10. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ, Yang J, Shu S, Rosenberg SA.
    J Immunol; 1986 May 15; 136(10):3899-909. PubMed ID: 2871106
    [Abstract] [Full Text] [Related]

  • 11. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.
    Papa MZ, Vetto JT, Ettinghausen SE, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Nov 15; 46(11):5618-23. PubMed ID: 3489525
    [Abstract] [Full Text] [Related]

  • 12. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Nov 15; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 13. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
    Mulé JJ, Shu S, Rosenberg SA.
    J Immunol; 1985 Jul 15; 135(1):646-52. PubMed ID: 3889158
    [Abstract] [Full Text] [Related]

  • 14. Augmentation of interleukin-2 immunotherapeutic effects by lymphokine-activated killer cells and allogeneic stimulation in murine tumor cells.
    Eggermont AM, Steller EP, Ottow RT, Matthews W, Sugarbaker PH.
    J Natl Cancer Inst; 1987 Nov 15; 79(5):983-90. PubMed ID: 3500357
    [Abstract] [Full Text] [Related]

  • 15. Systematic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease.
    Talmadge JE, Phillips H, Schindler J, Tribble H, Pennington R.
    Cancer Res; 1987 Nov 01; 47(21):5725-32. PubMed ID: 3499218
    [Abstract] [Full Text] [Related]

  • 16. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 17. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N, Ozaki A, Ishihara J, Sakurai M, Sasaki Y, Takahashi H, Sano T, Hoshi A.
    Gan To Kagaku Ryoho; 1986 Apr 01; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [Abstract] [Full Text] [Related]

  • 18. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK, Leland P.
    Lymphokine Cytokine Res; 1992 Jun 01; 11(3):133-9. PubMed ID: 1391232
    [Abstract] [Full Text] [Related]

  • 19. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA.
    J Biol Response Mod; 1984 Oct 01; 3(5):501-11. PubMed ID: 6389777
    [Abstract] [Full Text] [Related]

  • 20. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.